Physician profile
Sagun Pendse
NPI 1295788941
$4,509.22
in general payments reported to CMS, 2019-2025
28 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $547 · 2021: $608 · 2022: $624 · 2023: $412 · 2024: $853 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $749.35 | 2019-2025 | Clareon, Tryptyr, Argos |
| Allergan, INC. | $559.44 | 2019-2021 | |
| Biotissue Holdings INC. | $397.62 | 2020-2025 | |
| Rxsight INC | $370.71 | 2021-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $319.73 | 2019-2024 | Tecnis Iol, Tecnis Iol, Catalys System |
| Sun Pharmaceutical Industries INC. | $295.23 | 2019-2025 | Cequa |
| Abbvie INC. | $269.73 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $219.68 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $188.77 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $158.47 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $150.39 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.79 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $118.83 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $108.76 | 2023-2025 | Infuse, Biotrue, Vyzulta |
| Genentech USA, INC. | $75.31 | 2023-2025 | Vabysmo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.64 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $50.96 | 2023-2025 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $40.49 | 2023-2024 | Syfovre |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Horizon Therapeutics Plc | $31.65 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $23.61 | 2019 | |
| Sight Sciences, INC. | $23.08 | 2022 | |
| Ani Pharmaceuticals, INC. | $22.15 | 2025 | Yutiq |
| Tearlab Corp | $20.35 | 2021 | |
| Shire North American Group INC | $20.23 | 2019 | |
| Thea Pharma INC. | $20.10 | 2024 | Iyuzeh |
| Ivantis, INC | $14.34 | 2021 | |
| Ocular Therapeutix, INC. | $14.01 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagun Pendse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.